36 results on '"Jacobson, Ira"'
Search Results
2. Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure
3. Letter to the editor: Both universal screening and vaccination are essential components of a multipronged approach to hepatitis B elimination
4. Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed
5. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus
6. Telaprevir-based treatment effects on hepatitis C virus in liver and blood
7. L159F and V321A Sofosbuvir Treatment-Emergent HCV NS5B Substitutions: 43
8. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens
9. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study
10. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial
11. Determinants of Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis: 959
12. Absolute and Relative Contraindications to Pegylatedinterferon (PEG-IFN) or Ribavirin (RBV) in the US General Patient Population with Chronic Hepatitis C (HCV): Results from US Database of Over 45,000 Patients: 945
13. The Safety of Telaprevir in the Absence of Interferon and/or Ribavirin: Analysis of On-Treatment Data from the ZENITH Trial: 786
14. Factors Associated with the Lack of Achievement of Normal ALT in Chronic Hepatitis B (CHB) Patients Treated with Tenofovir DF (TDF) for up to 5 Years: 411
15. Six Years of Treatment with Tenofovir DF for Chronic Hepatitis B Virus Infection is Safe and Well Tolerated and Associated with Sustained Virological, Biochemical and Serological Responses with no Detectable Resistance: 374
16. Once Daily Sofosbuvir (GS-7977) plus PEG/RBV: High Early Response Rates Are Maintained During Post-Treatment Follow-Up In Treatment-Naïve Patients With HCV Genotype 1, 4, and 6 Infection in the ATOMIC Study: 230
17. Evaluation of Liver And Plasma HCV RNA Kinetics And Telaprevir Levels In Genotype 1 HCV Patients Treated With Telaprevir (TVR) Using Serial Fine Needle Aspirates (FNA): 215
18. Safety and efficacy of ritonavir-boosted danoprevir (DNVr), peginterferon α-2a (40KD) (P) and ribavirin (R) with or without mericitabine in HCV genotype (G)1-infected treatment-experienced patients with advanced hepatic fibrosis: 82
19. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) ± peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study: 81
20. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin
21. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients
22. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C
23. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus
24. Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype 1
25. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial
26. Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus
27. WIN-R revisited: Response to editorial
28. 1227 Delayed recovery of pegylated interferon and ribavirin induced anemia
29. 1213 Erythropoietin maintains ribavirin dose and sustained virologic response during HCV treatment
30. 1195 Seizures during pegylated interferon and ribavirin therapy for chronic hepatitis C in the WIN-R trial
31. 1190 Diabetes mellitus of new onset during pegylated interferon and ribavirin therapy for chronic hepatitis C: observations from the WIN-R trial
32. 630 Hepatocyte proliferation in hepatitis C: Correlation with degree of liver injury and serum alpha-fetoprotein
33. 345 Depression during IFN-ALFA plus ribavirin therapy: prevalence and prediction
34. 344 Depressive symptoms during IFN-alpha/ribavirin therapy are associated with reduced viral clearance in patients with hepatitis C
35. 312 Treatment of chronic hepatitis C with ISIS 14803, an antisense inhibitor of HCV, given for 12 weeks
36. Epidemiology and clinical impact of hepatitis D virus (delta) infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.